Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 10—October 2021
Research Letter

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19

Daniele Focosi, Federica Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla Gasperina, Andreina BajComments to Author , and Fabrizio Maggi
Author affiliations: Pisa University Hospital, Pisa, Italy (D. Focosi); Azienda Socio-Sanitaria Territoriale, Varese, Italy (F. Novazzi, F. Dentali, A. D. Dalla Gasperina, A. Baj, F. Maggi); University of Insubria, Varese, (A. Genoni, F. Dentali, D. Dalla Gasperina, A. Baj, F. Maggi)

Main Article

Figure

Evolution of SARS-CoV-2 variants in a patient who had coronavirus disease who was given bamlanivimab and etesivimab, Italy. Ct, cycle threshold; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure. Evolution of SARS-CoV-2 variants in a patient who had coronavirus disease who was given bamlanivimab and etesivimab, Italy. Ct, cycle threshold; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

Page created: July 23, 2021
Page updated: September 19, 2021
Page reviewed: September 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external